Joyzyme Group

Joyzyme Group Equity

The The Equity of Joyzyme Group (8622.HK) as of Oct 10, 2026 is 51.15 M CNY. In the previous year, The Equity was 46.33 M CNY — a change of 10.42% (higher).

Equity

51.15 MCNY

YoY

10.42%

Last updated:

In 2025, Joyzyme Group's equity was 51.15 M CNY, a 10.42% increase from the 46.33 M CNY equity in the previous year.

The Joyzyme Group Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
71.02 M CNY
Jan 1, 2019
70.69 M CNY
Jan 1, 2020
61.86 M CNY
Jan 1, 2021
49.46 M CNY
Jan 1, 2022
56.52 M CNY
Jan 1, 2023
43.73 M CNY
Jan 1, 2024
46.33 M CNY
Jan 1, 2025
51.15 M CNY
The Joyzyme Group Equity history
YEAREquityYoY
51.15 MCNY+10.42%
46.33 MCNY+5.94%
43.73 MCNY-22.63%
56.52 MCNY+14.28%
49.46 MCNY-20.04%
61.86 MCNY-12.49%
70.69 MCNY-0.47%
71.02 MCNY+89.95%
37.39 MCNY+54.50%
24.20 MCNY+53.41%
15.78 MCNY—
Access this data via the Eulerpool API

Joyzyme Group Stock analysis

What does Joyzyme Group do? Huakang Biomedical Holdings Co Ltd is a leading company in the field of biomedical research and development. It was founded in 2004 and is headquartered in Shenzhen, China. The company is listed on the Hong Kong Stock Exchange (HKEX: 8622) and has branches in various countries, including Germany and the USA. Answer: Huakang Biomedical Holdings Co Ltd is a leading company in the field of biomedical research and development. It was founded in 2004 and is headquartered in Shenzhen, China. The company is listed on the Hong Kong Stock Exchange (HKEX: 8622) and has branches in various countries, including Germany and the USA. Joyzyme Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Joyzyme Group's Equity

Joyzyme Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Joyzyme Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Joyzyme Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Joyzyme Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Joyzyme Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Joyzyme Group stock

The Equity of Joyzyme Group is 51.15 M CNY in 2025.

The Equity of Joyzyme Group changed from 46.33 M CNY to 51.15 M CNY, representing a 10.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Joyzyme Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Joyzyme Group historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Joyzyme Group

All Key Metrics — Joyzyme Group